Drug Database
CI

ciprofloxacin (Aceoto / Cetraxal / Cetraxal Otico)

✓ Approved

Laboratorios SALVAT · Small Molecule · Small Molecule

What is ciprofloxacin?

ciprofloxacin is a small molecule developed by Laboratorios SALVAT. It is approved for therapeutic indications via others.

Drug Profile

Brand NamesAceoto, Cetraxal, Cetraxal Otico
CompanyLaboratorios SALVAT
Drug ClassSmall Molecule
RouteOthers
StatusApproved

Therapeutic Indications

ciprofloxacin is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsOtitis externa✓ Approved
Ear and labyrinth disordersExternal ear inflammation✓ Approved

Related Research Articles

PubMedbioRxiv : the preprint server for biology2026-07-17

In vitro evaluation of the activity of pairwise combinations of zoliflodacin, gepotidacin, and ciprofloxacin against Neisseria gonorrhoeae.

Bowcutt Bailey B, Mukherjee Aditi A, Palace Samantha G SG, Grad Yonatan H YH

Two new antibiotics, zoliflodacin and gepotidacin, were recently approved for the treatment of urogenital gonorrhea. While combination therapy could, in principle, delay the emergence and spread of resistance, doing so depends on the absence of antagonism between the co-administered drugs. Using in vitro checkerboard testing, we observed no evidence of antagonism for all pairwise combinations of zoliflodacin, gepotidacin, and ciprofloxacin, including in strains with elevated ciprofloxacin MICs.

PubMedThe Laryngoscope2026-07-17

In Reference to Safety Profile of Nebulized Ciprofloxacin-Dexamethasone After Pediatric Airway Surgery.

Kazachkov Mikhail M

PubMedThe Laryngoscope2026-07-17

In Response to Safety Profile of Nebulized Ciprofloxacin-Dexamethasone After Pediatric Airway Surgery.

Landini Abbey L AL, Abrahamson Cyrus W CW, Frost Maya M, Spielberg David D et al.

PubMedFrontiers in microbiology2026-07-17

Genome-wide investigation of outbreak-associated Vibrio cholerae in Gujarat, India identifies antimicrobial resistance genes, virulence determinants, and mobile genetic elements.

Bhure Minal M, Shukla Nitin N, Purohit Harshal H, Patel Nimesh N et al.

This study investigates the 2024 cholera outbreak in Gujarat, India, utilizing combined whole-genome analysis of clinical Vibrio cholerae isolates and wastewater surveillance. A total of, 69 V. cholerae isolates were recovered from affected patients, predominantly belonging to the O1 serogroup (51 isolates). Antimicrobial susceptibility test (AST) of 34 isolates revealed complete resistance to ampicillin and partial resistance to cotrimoxazole, whereas all isolates were susceptible to doxycycline, ciprofloxacin, chloramphenicol, tetracycline, and gentamicin. Whole-genome sequencing of 20 selected isolates revealed that the isolates belong to the seventh pandemic El Tor (7PET) lineage, sequence type ST69. Phylogenomic analyses using a multi-method approach, core genes, Composition Vector (CV) Tree, SNPs, and multilocus sequence typing (MLST) showed tight clustering with limited diversity among the isolates. All isolates contained 13-15 antimicrobial resistance genes, with high consistency between genotype-phenotype for most antibiotics, although discordance was observed for ciprofloxacin, cotrimoxazole, and chloramphenicol. Sixteen genes were identified as virulence factors, and 11 isolates also had ctxA/ctxB. All isolates also had two to four integrative conjugative elements (ICEs) containing antimicrobial resistance genes (ARGs) and important Vibrio cholerae pathogenicity islands (VPI-1, VPI-2) and Vibrio cholerae seventh pandemic islands (VSP-1, VSP-2). The pangenome analysis highlights extensive genomic flexibility within species, likely driven by horizontal gene transfer and ecological adaptation; however, further outbreak-specific investigations are required to determine their direct role in current outbreak. The detection of ctxA-positive signals in wastewater, 20% (28/140) of the samples, suggests a possible surveillance signal during the outbreak. These results highlight the presence of antimicrobial-resistant 7PET O1 El Tor strains in Gujarat outbreaks and support continued genomic monitoring to guide focused public health interventions in endemic areas. Furthermore, this study also underscores the importance of wastewater surveillance for monitoring V. cholerae.

PubMedNanoscale advances2026-07-17

Gold nanoparticle-deposited reduced dendritic fibrous nanotitania for enhanced photocatalytic performance.

Nguyen Thanh Nhan TN, Yoo Jaejun J, Kim Jinhee J, Rosyadi Anisa Fitriani AF et al.

In recent decades, extensive research has focused on developing titania for photocatalysis, photovoltaics, and energy storage. Metal doping, electronic structure modification, and morphological design are effective strategies to enhance the performance of titania for these applications. In this study, we report the fabrication of hybrid nanostructures of gold nanoparticles (AuNPs) anchored on reduced dendritic fibrous nanotitania (R-DFNT) (Au/R-DFNT) via a chemical reduction method. The hierarchical structure of R-DFNT not only facilitates rapid mass transport but also maximizes the exposure of abundant defect species as nucleation sites for anchoring gold nucleation, resulting in well-dispersed AuNPs on R-DFNT. The photocatalytic performance of Au/R-DFNT nanocomposites is evaluated through the photodegradation of ciprofloxacin (CP). The optimized Au/R-DFNT sample exhibits outstanding photocatalytic activity towards CP degradation, with a kinetic rate constant of 0.0111 min-1, which is 2.3, 25.5, and 4.1 times higher than those of pristine R-DFNT, reduced commercial P25, and the AuNPs/reduced-P25 nanocomposite, respectively. The superior photocatalytic efficiency of Au/R-DFNT is mainly attributed to its dendritic fibrous morphology, the abundance of exposed defect sites, and the well-formed gold-titania heterojunction, which facilitates charge-transfer and prolongs the lifetime of charge carriers.

PubMedFrontiers in pharmacology2026-07-17

Intraperitoneal administertion: compatibility and stability of common antibiotics in amino acid-based peritoneal dialysate.

Zhang Bohua B, Zhong Lichao L, Zhou Xueli X, Zhong Hui H et al.

The preferred method of antibiotic administration for peritoneal dialysis-related peritonitis is intraperitoneal. However, there are few studies on the compatibility of antibiotics in amino acid-based peritoneal dialysate. Our study employed High Performance Liquid Chromatography (HPLC) and amino acid analyzer to evaluate the stability of different antibiotics in amino acid-based peritoneal dialysate. We also used the two-dose method to detect the antimicrobial potency of gentamicin. Gentamicin, ciprofloxacin, heparin Sodium and fluconazole showed excellent stability under different conditions (14 days at 4 °C: ≤3.57%, 14 days at 25 °C: ≤3.77%). β-Lactam antibiotics including meropenem, ceftazidime, cefotaxime, and aztreonam showed significant degradation, especially at high temperature (37 °C)(14 days at 4 °C: ≤59.98%, 14 days at 25 °C: 19.06%-84.97%, except for aztreonam demonstrating degradation at 48 h at 37 °C (18.51%-41.88%). Among them, meropenem was the least stable (14 days at 4 °C: 59.98%, 14 days at 25 °C: 84.97%). Low concentration vancomycin is relatively stable, while medium and high concentration vancomycin has poor stability (14 days at 4 °C 500 mg/L: 45.8%, 1 g/L 27.7%). Most amino acids remained basically stable under different antibiotic environments. We counted the degradation rate of all amino acids under different conditions. The maximum degradation rate appeared on glycine, but it was only 8.21%. Finally, we also found that the antibacterial efficacy of gentamicin in acid-based peritoneal dialysate was enhanced. Most antibiotics are stable in amino acid-based peritoneal dialysate. However, β-lactams (especially meropenem, ceftazidime, and cefotaxime) and medium-to-high dose vancomycin showed significant degradation and require prompt administration. The nutritional amino acid profile in dialysate remains largely unaffected. Gentamicin demonstrates enhanced antibacterial activity in the amino acid-based peritoneal dialysate.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ciprofloxacin